A key factor driving the market’s growth is the growing demand for non-dextran IV iron drugs. Several IV iron complexes are available for the treatment of iron deficiency anemia. Iron dextran is associated with a high risk of anaphylactic reactions, whereas others must be administered in numerous small infusions to avoid labile iron reactions. The demand has shifted from conventional dextran IV iron drugs to non-dextran IV iron drugs.
This market research report on the global iron drugs market 2018-2022 provides an analysis of the most important trends expected to impact the market outlook during the forecast period. Technavio predicts an emerging trend as a major factor that has the potential to significantly impact the market and contribute to its growth or decline.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
In this report, Technavio highlights the vendor focus on expanding the reach of IV iron drugs as one of the key emerging trends in the global iron drugs market:
Global iron drugs market: Vendor focus on expanding the reach of IV iron drugs
Vendors are focusing on strategies to expand the reach and scope of IV iron drugs. For instance, a major vendor is looking to consolidate its presence in the market by expanding the reach of its flagship IV iron drug. The number of units sold of the flagship IV iron drug increased significantly across the world in 2015. This was because of the strong demand in Australia, Germany, Spain, the Nordic countries, the UK, and Ireland.
“Several companies are strengthening their position by conducting disease awareness programs, clinical trials, and medical education support for physicians. One of the research products is the study on people with chronic heart failure and iron deficiency. Such initiatives will increase the adoption of iron drugs in the forecast period,” says a senior analyst at Technavio for research on infectious and rare diseases.
Global iron drugs market: Segmentation analysis
This market research report segments the global iron drugs market into the following products (oral drug and IV drug) and key regions (the Americas, APAC, and EMEA).
The oral drug segment held the largest market share in 2017, accounting for more than 52% of the market. This product segment is expected to dominate the global market throughout the forecast period.
The Americas held the highest share of the global iron drugs market in 2017, accounting for a market share of approximately 44%. This region is anticipated to dominate the global market throughout the period 2018-2022.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market sizing
- Market size and forecast
Five Forces Analysis
- Regional comparison
- Key leading countries
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at email@example.com.